Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Price Quote as of

Today's Trading

Day Low 1.24
Day High 1.34
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Resverlogix Provides Update Regarding Extension of its Filing Calendar
- GlobeNewswire - Fri Sep 25, 5:30PM CDT
GlobeNewswire - CMTX
Fri Sep 25, 5:30PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that further to its September 11, 2020 press release, it continues to expect to file its interim financial statements and related MD&A for the three months ended July 31, 2020 (the "Interim Filings") on or about October 5, 2020.
Resverlogix Announces Publication in High-impact Peer-reviewed Journal - Medicinal Research Reviews
- GlobeNewswire - Tue Sep 15, 7:00AM CDT
GlobeNewswire - CMTX
Tue Sep 15, 7:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Inhibitors of bromodomain and extra�?�terminal proteins for treating multiple human diseases", in the peer-reviewed Medicinal Research Reviews.
Resverlogix Provides Update Regarding Extension of its Filing Calendar
- GlobeNewswire - Fri Sep 11, 7:18PM CDT
GlobeNewswire - CMTX
Fri Sep 11, 7:18PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has filed its annual financial statements for the year ended April 30, 2020, related MD&A and annual information form pursuant to National Instrument 51-102 (collectively, the "Annual Filings"). The Company had previously relied on exemptive relief issued by provincial securities commissions - due to the COVID-19 outbreak - to extend the date of filing of its Annual Filings for the year ended April 30, 2020. These filings can be found at under the Company's profile.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.75 +70.67% increase
on 09/03/20
Period Open:0.83
Price movement based on the high, low and last over the given period.
1.52 -15.79% decrease
on 09/28/20
+0.45 (+54.22%) increase
since 08/28/20
3-Month 0.70 +82.86% increase
on 08/05/20
Period Open:0.82
Price movement based on the high, low and last over the given period.
1.52 -15.79% decrease
on 09/28/20
+0.46 (+56.10%) increase
since 06/30/20
52-Week 0.56 +128.57% increase
on 06/09/20
Period Open:0.67
Price movement based on the high, low and last over the given period.
1.94 -34.02% decrease
on 11/11/19
+0.61 (+91.04%) increase
since 09/30/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies